155 related articles for article (PubMed ID: 16550756)
1. Reply to Yang et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Mandal A
Clin Nephrol; 2006 Mar; 65(3):227; author reply 227-8. PubMed ID: 16550756
[No Abstract] [Full Text] [Related]
2. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
3. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
Courtney AE; McNamee PT; Nelson WE; Maxwell AP
Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
[TBL] [Abstract][Full Text] [Related]
4. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of RAS inhibitor in IgA nephropathy].
Kashihara N
Nihon Jinzo Gakkai Shi; 2008; 50(4):473-7. PubMed ID: 18546877
[No Abstract] [Full Text] [Related]
6. Quantitative appraisal of treatment options for IgA nephropathy.
Ballardie FW
J Am Soc Nephrol; 2007 Nov; 18(11):2806-9. PubMed ID: 17942959
[TBL] [Abstract][Full Text] [Related]
7. IgA nephritis--ACE inhibitors, steroids etc?
Wardle EN
Nephrol Dial Transplant; 2007 Jun; 22(6):1785; author reply 1785. PubMed ID: 17403702
[No Abstract] [Full Text] [Related]
8. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
9. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
10. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
Opelz G; Zeier M; Laux G; Morath C; Döhler B
J Am Soc Nephrol; 2006 Nov; 17(11):3257-62. PubMed ID: 17035607
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
Brackbill ML; Bashaw-Keaton R; Sytsma CS
Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
[TBL] [Abstract][Full Text] [Related]
13. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
[TBL] [Abstract][Full Text] [Related]
16. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Ferrari P
Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
[TBL] [Abstract][Full Text] [Related]
17. Crescentic IgA nephropathy in a child: Effect of a new combination therapy.
Okamoto M; Yokoyama N; Nozu K; Nakanishi K; Yoshikawa N
Pediatr Int; 2017 Apr; 59(4):501-503. PubMed ID: 28244692
[No Abstract] [Full Text] [Related]
18. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
Chin Med J (Engl); 2008 Nov; 121(21):2167-71. PubMed ID: 19080179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
